Skip to main content

Arcpoint Inc(ARC-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.010
Day High0.010
Open:0.010
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Arcpoint Inc

Select a category then submit the form to load news
Newswire.ca
ARC RESOURCES LTD. CONFIRMS QUARTERLY DIVIDEND OF $0.21 PER SHARE FOR JANUARY 15, 2026
GlobeNewswire
ARCPOINT REPORTS Q1 2025 FINANCIAL RESULTS
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
GlobeNewswire
ARCPOINT REPORTS 2024 YEAR END FINANCIAL RESULTS AND ANNOUNCES MANAGEMENT CHANGE
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)
GlobeNewswire
ARCPOINT ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT AND ANNOUNCES UPSIZE
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
GlobeNewswire
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q3 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE
GlobeNewswire
ARCPOINT GRANTS DEFERRED SHARE UNITS
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
GlobeNewswire
ARCPOINT PROVIDES CORPORATE UPDATE ON BENEFITS OF CRESSO TRANSACTION
GlobeNewswire
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q2 FINANCIAL RESULTS AND NEW OPPORTUNITIES
GlobeNewswire
ANY LAB TEST NOW AND ARCPOINT CREATE LARGEST FRANCHISE DIRECT ACCESS LAB TESTING GROUP IN THE UNITED STATES
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)
GlobeNewswire
ARCPOINT ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT AND WARRANT AMENDMENTS
GlobeNewswire
ARCPOINT ANNOUNCES PROPOSED SHARES FOR DEBT SETTLEMENT
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
GlobeNewswire
ARCPOINT ANNOUNCES C$1.5 MILLION NON-BROKERED PRIVATE PLACEMENT
GlobeNewswire
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q1 FINANCIAL RESULTS
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)
GlobeNewswire
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2023 Q4 AND FULL YEAR FINANCIAL RESULTS
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ARC)
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)
GlobeNewswire
ARCPOINT ANNOUNCES CLOSING OF US$1.1 MILLION NON-BROKERED PRIVATE PLACEMENT
AI-generated - The Globe and Mail
ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)
GlobeNewswire
ARCPOINT ANNOUNCES US$1.6 MILLION NON-BROKERED PRIVATE PLACEMENT
GlobeNewswire
ARCPOINT ISSUES SHARES TO SETTLE DEBT
GlobeNewswire
ARCPOINT AND MD CARE GROUP COLLABORATE TO OFFER MORE COMPLETE HEALTHCARE OPTIONS AND SOLUTIONS
GlobeNewswire
ARCPOINT TO HOST CONFERENCE CALL TO PROVIDE BUSINESS UPDATE AND DISCUSS 2023 Q3 FINANCIAL RESULTS

Profile

ARCpoint Inc is a U.S-based franchise system providing drug testing, alcohol screening, DNA and clinical lab testing, corporate wellness programs, and employment and background screening, among other services. The platform also digitalizes and streamlines administrative functions such as materials purchasing, compliance, billing, and physician services for ARCpoint franchise labs and other clients. Its segments include: AFG Service; and Others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.